"Preview" Icon

Remimazolam

Need More Information?

Read answers to frequently asked questions about BioHarmony's centralized semantic drug data sets and what they can do for you on our

Byfavo (remimazolam) is a small molecule pharmaceutical. Remimazolam was first approved as Byfavo on 2020-10-06. It has been approved in Europe to treat conscious sedation. The pharmaceutical is active against gamma-aminobutyric acid receptor subunit beta-3, gamma-aminobutyric acid receptor subunit alpha-1, gamma-aminobutyric acid receptor subunit gamma-2, gamma-aminobutyric acid receptor subunit alpha-5, gamma-aminobutyric acid receptor subunit beta-2, gamma-aminobutyric acid receptor subunit alpha-2, gamma-aminobutyric acid receptor subunit alpha-6, gamma-aminobutyric acid receptor subunit alpha-3, gamma-aminobutyric acid receptor subunit alpha-4, gamma-aminobutyric acid receptor subunit beta-1, gamma-aminobutyric acid receptor subunit delta, gamma-aminobutyric acid receptor subunit epsilon, gamma-aminobutyric acid receptor subunit gamma-1, gamma-aminobutyric acid receptor subunit gamma-3, gamma-aminobutyric acid receptor subunit pi, and gamma-aminobutyric acid receptor subunit theta. Byfavo’s patents are valid until 2033-04-30 (FDA).

$4,995

Want to know more?
Schedule a demo or contact us for additional purchasing options.

Trade Name

 Byfavo

Common Name

 remimazolam

ChEMBL ID

 CHEMBL4297526

Indication

 conscious sedation

Drug Class

Image (chem structure or protein)

Remimazolam structure rendering

$4,995

Want to know more?
Schedule a demo or contact us for additional purchasing options.

Every Drug Dataset Includes...

Full Drug Information

Including:

Trade name (FDA, EMA)

Drug common name

Description

Classification

Drug class

Image (chemical or protein structure)

Protein Data Bank ID

Structure (InChI/SMILES or Protein Sequence)

CAS-ID

RxCUI

ChEMBL ID

ChEBI ID

PubChem CID

DrugBank ID

Indications

Including:

Agency approved indications

Phase 1 Indications

Phase 2 Indications

Phase 3 Indications

Phase 4 Indications

MeSH identifiers

Ontology identifiers

Target Information

Including:

Agency Approved Targets

Alternative Targets

Gene name

Gene synonyms

NCBI Gene ID

Protein name

Protein synonyms

Uniprot ID

Orthologs

Clinical Variant Information

Including:

ClinVar ID

Target mutation

Effect

Evaluation date

PharmGKB level

Clinical Trial Information

Including:

NCT ID

Trial Timeline

Results

Phase

Expanded Access

Official Title

Sponsor

Indications / Phase Indications

Study Type

Enrollment

Inclusion Criteria

Exclusion Criteria

Links to Clinical Trials

Reimbursement Codes

Including:

ICD-10

ATC

HCPCS

Safety Information

Including:

Black Box Warnings

Adverse Events

Adverse Reactions

Expedite Criteria

Trend Information

Including:

Top, trending, and new metadata terms in the following categories:

Disease or Syndrome

Pharmacological Substances

Biological Entities

Laboratory Procedures

Commercial Information

Including:

Company (FDA, EMA)

Approval Date (FDA, EMA)

Exclusivity

Patent Expiration

Generics and Biosimilars (FDA, EMA)

Drug Labels

Economic Information

Including:

Company

Annual revenue

Quarterly revenue

Global sales

US sales

Non-US sales

Full dataset compatible with-

SQL logo
SQL for web applications
<strong>R</strong> for statistical modeling
R for statistical modeling
Spotfire and tableau logos
Spotfire & Tableau for visualization
<strong>CSV</strong> export file format
CSV export file format
JSON logo
JSON export file format
XLSX logo
XLSX export file format

Continually updated information available as a yearly subscription for individual drug-of-interest.

$4,995

Schedule a demo to see what you get or contact us for additional or enterprise purchasing options.